Decheng Capital LLC
- SEC CIK
- 0002010850
- Latest filing
- Aug 14, 2026
Holdings in Q2 2026
Holdings as of Jun 30, 2026, filed Aug 14, 2026. Long positions only; changes compare share counts with Q1 2026.
- Positions
- 14
- 0 vs. Q1 2026
- Portfolio value
- $731.7M
- +$70.4M (+10.7%) vs. Q1 2026
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| CGONCG Oncology, Inc. | COM | 6,371,669 | $452.7M | 61.9% | 00.0% | Unchanged | History |
| NUVBNuvation Bio Inc. | COM CL A | 25,954,439 | $147.4M | 20.1% | 00.0% | Unchanged | History |
| AARDAardvark Therapeutics, Inc. | COM | 3,917,299 | $22.6M | 3.1% | 00.0% | Unchanged | History |
| ACRSAclaris Therapeutics, Inc. | COM | 4,041,736 | $21.4M | 2.9% | 00.0% | Unchanged | History |
| UPBUpstream Bio, Inc. | COM | 2,724,868 | $18.9M | 2.6% | 00.0% | Unchanged | History |
| RCUSArcus Biosciences, Inc. | COM | 464,779 | $14.3M | 2.0% | −13,040−2.7% | Reduced | History |
| EQEquillium, Inc. | COM | 4,447,308 | $14.2M | 1.9% | 00.0% | Unchanged | History |
| RVMDRevolution Medicines, Inc. | COM | 52,667 | $9.86M | 1.3% | −40,833−43.7% | Reduced | History |
| LYELLyell Immunopharma, Inc. | COM | 692,050 | $9.72M | 1.3% | 00.0% | Unchanged | History |
| BYSIBeyondSpring Inc. | SHS | 3,800,702 | $6.65M | 0.9% | 00.0% | Unchanged | History |
| ZNTLZentalis Pharmaceuticals, Inc. | COM | 1,323,327 | $6.42M | 0.9% | 00.0% | Unchanged | History |
| NAMSNewAmsterdam Pharma Co N.V. | ORDINARY SHARES | 176,887 | $5.99M | 0.8% | −148,170−45.6% | Reduced | History |
| PYXSPyxis Oncology, Inc. | COMMON STOCK | 326,810 | $983.7K | 0.1% | 00.0% | Unchanged | History |
| TNGXTango Therapeutics, Inc. | COM | 20,000 | $625.2K | 0.1% | +20,000 | New | History |
Sold out since Q1 2026 (1)
Positions held at the end of Q1 2026 that are gone from this filing.